Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years

Long-term safety and efficacy data on the iron chelator deferiprone in sickle cell disease (SCD) and other anemias are limited. FIRST-EXT was a 2-year extension study of FIRST (Ferriprox in Patients With Iron Overload in Sickle Cell Disease Trial), a 1-year, randomized noninferiority study of deferi...

Descripción completa

Detalles Bibliográficos
Autores principales: Elalfy, Mohsen S., Hamdy, Mona, El-Beshlawy, Amal, Ebeid, Fatma S. E., Badr, Mohamed, Kanter, Julie, Inusa, Baba, Adly, Amira A. M., Williams, Suzan, Kilinc, Yurdanur, Lee, David, Fradette, Caroline, Rozova, Anna, Temin, Noemi Toiber, Tricta, Fernando, Kwiatkowski, Janet L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979751/
https://www.ncbi.nlm.nih.gov/pubmed/36018224
http://dx.doi.org/10.1182/bloodadvances.2021006778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979751/
https://www.ncbi.nlm.nih.gov/pubmed/36018224
http://dx.doi.org/10.1182/bloodadvances.2021006778

Ejemplares similares